BMS-188797

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C47H51NO15
Molecular Weight	869.9055
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]4(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C5=CC=CC=C5)C6=CC=CC=C6)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]7OC[C@@]27OC(=O)OC)C4(C)C

InChI

InChIKey=GMJWGJSDPOAZTP-MIDYMNAOSA-N

InChI=1S/C47H51NO15/c1-25-30(61-42(55)35(51)34(27-16-10-7-11-17-27)48-40(53)28-18-12-8-13-19-28)23-47(57)39(62-41(54)29-20-14-9-15-21-29)37-45(5,38(52)36(60-26(2)49)33(25)44(47,3)4)31(50)22-32-46(37,24-59-32)63-43(56)58-6/h7-21,30-32,34-37,39,50-51,57H,22-24H2,1-6H3,(H,48,53)/t30-,31-,32+,34-,35+,36+,37-,39-,45+,46-,47+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C47H51NO15
Molecular Weight	869.9055
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16333310 | http://www.rsc.org/suppdata/np/c4/c4np00064a/c4np00064a1.pdf

Bristol-Myers Squibb developed BMS-188797 for the potential treatment of solid tumors. BMS-188797 causes G2/M cell cycle arrest and exhibits potent antiproliferative activity against human tumor cell. BMS-188797 in combination with cisplatin successfully has passed phase I clinical and has been recommended for further phase II trials. However, further development has been halted.

Originator

Approval Year

PubMed

Title	Date	PubMed
Preclinical antitumor activity of two novel taxanes.	2001	11269747
The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells.	2001 Oct 1	11567829
A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.	2006 Jan 16	16333310

Patents

Sample Use Guides

In Vivo Use Guide

a fixed dose of carboplatin was combined with a dose escalation schedule of BMS-188797 ( 100, 125, 150, and 175 mg/m2 ), both administered once every 3 weeks, in patients with advanced solid malignancies.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:43:51 GMT 2023` Edited by `admin` on `Fri Dec 15 15:43:51 GMT 2023`
Record UNII	0HG7S0S581
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-188797

Common Name

English

4-Desacetylpaclitaxel 4-methyl carbonate [WHO-DD]

Common Name

English

4-DESACETYLPACLITAXEL 4-METHYL CARBONATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1490